OrbiMed and SR One led a $60m Series B round in Avenzo Therapeutics.

OrbiMed, a private equity firm, and SR One, a venture capital firm, led a $60m Series B round in Avenzo Therapeutics, a biotechnology company, with participation from Foresite Capital, Lilly Asia Ventures, Surveyor Capital, New Enterprise Associates (NEA), Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital and Quan Capital. “We are excited to add Longwood to our syndicate and are grateful to all of our investors for their continued partnership as we strive to develop oncology therapies that help fight cancers with high unmet medical needs. Avenzo has made tremendous progress this year as we have advanced our pipeline from one to four clinical stage assets. This Series B financing enables us to build on this momentum as we continue the development of our potential best-in-class oncology programs,” Athena Countouriotis, Avenzo CEO.